|
Cardiac Arrhythmia Pilot Study (CAPS) Clinical Trials Data presented on Clinical Trials Search is not meant to be a substitute for qualified medical advice, visits or professional assistance with a genuine dr.. We are not doctors. Always consult your mD about Cardiac Arrhythmia Pilot Study (CAPS) conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. Cardiac Arrhythmia Pilot Study (CAPS) Clinical research trials and Cardiac Arrhythmia Pilot Study (CAPS) medical trials take place in many of places throughout the U.S.A.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually evaluate the effectiveness of new does drugs. The purpose of the studies / projects is to solve specific human healthcare questions. Clinical trials are a popular way for mDs, government agencies, and private sector companies to find cures for all varieties of conditions, like Cardiac Arrhythmia Pilot Study (CAPS). Cardiac Arrhythmia Pilot Study (CAPS) Clinical Trials and other clinical trials allow for volunteers to have health treatment options before they are available to the masses. Many times the human subjects acquire professional assistance for free of charge, and sometimes they are compensated for their time. Occasionally there is a cost for a Cardiac Arrhythmia Pilot Study (CAPS) clinical trial. Test subjects typically obtain the finest healthcare available for their Cardiac Arrhythmia Pilot Study (CAPS) condition. Dangers are a reality, nevertheless, and might include additional or frequent doctor trips, medical dangers (possibly life-jeopardising), and/or the treatment being ineffectual. Trials are federally regulated with strict guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "C" Clinical Trials Conditions > Cardiac Arrhythmia Pilot Study (CAPS)  Cardiac Arrhythmia Pilot Study (CAPS)
Cardiac Arrhythmia Pilot Study (CAPS)
For Condition: Arrhythmia,Cardiovascular Diseases,Heart Diseases,Ventricular Arrhythmia
Status: Completed
Sponsor(s): National Heart, Lung, and Blood Institute (NHLBI) ,
Synopsis: To compare the effectiveness of various drugs and drug combinations in suppressing complex ventricular arrhythmias, and to evaluate their safety.
Details: BACKGROUND: Epidemiologic studies had indicated that complex ventricular premature beats made an independent contribution to risk of sudden death in survivors of a myocardial infarction (MI), and did not appear to be merely a reflection of their association with relatively severe myocardial damage. The potential for reduction in mortality by identification and administration of drugs capable of safely suppressing ventricular arrhythmias was tremendous. In 1982, there was incomplete knowledge regarding which types of ventricular arrhythmias responded to various kinds of drugs. A pilot study of antiarrhythmic agents helped clarify this issue. Numerous antiarrhythmic agents with differing pharmacologic properties and side effects had been shown to suppress ventricular arrhythmias. It had also been postulated that antiarrhythmics might raise an individual's threshold for experiencing ventricular fibrillation. There had been several published reports of large (at least l00 patients), long-term clinical trials of antiarrhythmic agents in post-MI patients. None of these had yielded statistically significant results using mortality as the response variable. This might have been due to incorrect drug selection, inadequate sample size, inappropriate choice of patients, or the lack of impact of arrhythmia treatment on mortality. Due to incomplete knowledge as to which drug(s) and combinations of drugs were most effective, it was considered to be premature to undertake a full scale trial in 1981-1982. However, the public health problem was of sufficient magnitude to warrant a pilot study to learn more about the efficacy and safety of various antiarrhythmic drugs singly or in combination. The protocol planning phase began in October l982. Patient recruitment started in July l983 and ended in the summer of 1985. Each patient was followed for one year. DESIGN NARRATIVE: Randomized, double-blind, fixed sample. A total of 502 patients were randomly assigned to 5 treatment groups consisting of encainide, ethmozine, flecainide, imipramine, and placebo.
Eligibility:
Study Type: Interventional, Treatment, Randomized, Double-Blind
Minimum Age/Maximum Age: 18 Years/75 Years
Genders: Both
Protocol Entry Criteria: Men and women. Patients had acute myocardial infarction and ventricular arrhythmias.
Total Enrollment:
Location and Contact Information:
Overall Study Official:
ToshioAkiyama, , University of Rochester
Additional Information:
Study ID Numbers: 23;
Study Start Date: September 1982
Record last reviewed: January 2000
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00000504
Other Heart Diseases Studies:
1. Heart Failure Adherence and Retention Trial (HART)
2. Low Literacy CVD Diet Education for Blacks
3. Basic Mechanisms of Meditation and Cardiovascular Disease in Older Blacks
4. SES, Health Behaviors and CVD Among Vietnam-Era Twins
5. Women's Angiographic Vitamin and Estrogen Trial (WAVE)
Related Studies:
Other Heart Diseases Clinical Trials
Other Clinical Trials
Other Clinical Trials
Cardiac Arrhythmia Pilot Study (CAPS)
|
|
|
|
|
|
|
|
